Cancer drug data release set to power next wave of therapeutic discovery

Unique data comparing almost 1,000 cancer cell lines’ responses to 453 licensed and experimental drugs is now freely available to the worldwide research community

This week (25 July) the Genomics of Drug Sensitivity in Cancer project (www.cancerrxgene.org) has released the results of four years of intense research to power genetic research into cancer treatment worldwide. The new data set builds on the previous six years’ study, and practically doubles the volume of novel data available on the website – making it the largest public dataset of its kind in the world.

This new data release brings the amount of freely available, open-access data on the website to 453 cancer treatment compounds, 989 cancer cell lines, 494,973 genomic associations and 386,293 drug dose response curves. The previous study has already enabled discoveries that led to drug trials of PARP inhibitors in childhood bone cancer, directly contributed to drug development in pharma, and powered 70 research studies across the globe. The datasets are accessed by over 350 users each day and this is set to increase with the new data release. The project team hope that this enhanced resource will help to power new discoveries and therapeutic options for many years to come.

The Genomics of Drug Sensitivity in Cancer project is a pioneering public-private partnership funded by Wellcome. It combines samples of hospital patients’ cancer cell lines with licensed and experimental cancer drugs from a number of pharmaceutical companies, and applies in-depth observation and genetic analysis to identify how the underlying changes in a person’s DNA affects how they will respond to treatment. The ultimate goal is to identify biomarkers that could be used in the clinic to identify which drugs will work best to treat a patient’s cancer, based on the tumour’s genetic profile.

Working together, the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA) have investigated samples from 30 different adult and paediatric cancers. The tumour types include blood cancers and solid tumours, primary and metastatic, common and rare. The novel data offers a rich resource with opportunities for cancer scientists to discover more about how cancer cells work, how they respond to treatment, and generate new therapeutics and drug combinations.

Now part of the Cancer Dependency Map (Cancer DepMap) project, the vast dataset is available on the www.cancerrxgene.org website.

“We are delighted that we have been able to create, and release, this valuable data to the global cancer research community. Our Genomics of Drug Sensitivity in Cancer database is the world’s largest repository for information on how a cancer’s underlying genomic landscape influences its response to cancer treatments. We hope it will provide new insights that will point to new ways to target, and treat individual tumours.”

Mathew Garnett Co-lead of the Genomics of Drug Sensitivity in Cancer project, and group leader at the Wellcome Sanger Institute

The team have further data releases planned for the near future.

Press Contact

If you need help or have any queries, please contact us using the details below.

Emily Mobley
Media Manager
Tel +44 (0)1223 496 851
Email: emily.mobley@sanger.ac.uk

 

Dr Matthew Midgley
Media Officer
Tel +44 (0)1223 494 856
Email: matthew.midgley@sanger.ac.uk

 

Dr Samantha Wynne
Media Officer
Tel +44 (0)1223 492 368
Email: samantha.wynne@sanger.ac.uk

 

Press office
Wellcome Sanger Institute, Hinxton,
Cambridgeshire, CB10 1SA, UK
Tel +44 (0) 7748 379849
Email: press.office@sanger.ac.uk

 

Selected websites

  • Wellcome Sanger Institute

    The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast – we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.

  • Wellcome

    Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation. www.wellcome.ac.uk